Venus Remedies has received its first patent from US PTO for its novel research product, Vancoplus. With this patent grant, which is valid up to December 2027, the company is set to tap the US market by launching the product.
Vancoplus has already been granted the patents from countries like South Africa, New Zleand and Ukraine. Vancoplus, a brand of Ceftriaxone and Vancomycin along with the chemical vector, used in CVMC technology, is the only remedy after vaccination to treat MRSA and multi drug resistant microbes which causes Meningities, Pneumonia, Typhoid, Septicemia, Urinary Treat infection, skin and skin infections and staphylococcal Endocarditis, The drug restricts the production of toxin by MRSA pathogens and also reduces the treatment time, cost and adverse affects.
Vancoplus which took more than seven years after its development to receive the US patent is intended to be launched in early 2014 through 505(b)(2) route.
